Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics to $115 from $110 and keeps a Buy rating on the shares. The company posted a fiscal Q3 beat continued momentum in Plasma and a strong performance in Blood Center, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HAE:
- Haemonetics raises FY23 adjusted EPS view to $2.90-$3.00 from $2.70-$3.00
- Haemonetics reports Q3 adjusted EPS 85c, consensus 80c
- Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
- Haemonetics price target raised to $110 from $100 at Mizuho
- ViewRay CFO to step down, William Burke to succeed